Premium
Imaging for staging bladder cancer: a clinical study of intravenous 111 indium‐labelled anti‐MUC1 mucin monoclonal antibody C595
Author(s) -
Hughes O.D.M.,
Perkins A.C.,
Frier M.,
Wastie M.L.,
Denton G.,
Price M.R.,
Denley H.,
Bishop M.C.
Publication year - 2001
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1046/j.1464-410x.2001.00985.x
Subject(s) - muc1 , medicine , monoclonal antibody , mucin , bladder cancer , scintigraphy , immunohistochemistry , pathology , antibody , cancer , radiology , immunology
Objective To investigate the clinical application of an 111 In‐labelled anti‐MUC1 mucin monoclonal antibody (mAb) imaging for staging invasive bladder cancer. Patients and methods Indirect immunohistochemistry was used to confirm the expression of the MUC1 target antigen by metastatic tumours. Twelve patients with bladder cancer (two with superficial and 10 with locally invasive/metastatic disease) underwent planar γ‐scintigraphy 48 h after an intravenous injection with 111 In‐labelled anti‐MUC1 mucin mAb C595. Results No bladder uptake was detected in the two patients with superficial disease, but scintigraphy showed primary and recurrent bladder tumours and metastases in nine of the remaining 10 patients with invasive disease. In three patients additional staging information was obtained from the mAb imaging which would have altered patient management. There were no reported side‐effects. Conclusion This study confirmed the ability of the mAb technique to detect both primary and recurrent invasive bladder tumours and distant metastases. Some lesions shown by mAb imaging were not detected by other methods. The use of mAb imaging has the potential to improve clinical staging and assist in selecting those patients most likely to benefit from radical therapy.